Genzyme wins recommendation for Mozobil use by NHS Wales

Genzyme has been given a recommendation for its stem cell therapy Mozobil to be used by NHS Wales to treat myeloma and lymphoma patients.

The All Wales Medicines Strategy Group (AWMSG) offered its backing for the Genzyme treatment, which helps to stimulate the number of stem cells in the blood stream to increase the success rate of transplantation procedures.

It comes after the Scottish Medicines Consortium recommended the use of Mozobil by NHS Scotland earlier this year, while a number of English authorities have also given positive testimonies on the treatment.

Rory Cameron, transplant and oncology business unit director for Genzyme UK, described AWMSG’s recommendation as “great news” for patients in Wales.

He added: “We are driven by our commitment to developing and delivering highly effective therapies to improve the lives of patients suffering from life-threatening diseases.”

Earlier this month, the company appointed David Meeker to the newly-created role of chief operating officer in order to improve its efficiency.